The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...
Albany Medical Center’s adult Cystic Fibrosis Care Center has been treating patients aged 18 and older living with cystic fibrosis (CF).
Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Ann & Robert H. Lurie Children’s Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...
Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly ...
Fund provides air purifiers & supplies to cystic fibrosis community impacted by wildfiresLos Angeles, CA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization ...
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...
Epicured Inc., an emerging health care company that develops, produces and distributes nutrition solutions to combat chronic disease and improve health outcomes, continues to expand its Life Sciences ...
Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK "This ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...